Immunomodulating Polynucleotides, Antibody Conjugates, Methods of Use
Summary
US Patent Application US20260109728A1, published April 23, 2026 with a filing date of May 28, 2025, discloses immunomodulating polynucleotides containing 5-modified uridine or cytidine residues, a total of 6 to 16 nucleotides, and abasic spacers or internucleoside phosphotriesters. The application also covers conjugates linking these polynucleotides to targeting moieties, pharmaceutical compositions containing stereochemically enriched internucleoside phosphorothioates, and methods of therapeutic use. Eleven inventors are named including Sukumar SAKAMURI, Curt W. BRADSHAW, and Joseph STOCK.
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
USPTO published patent application US20260109728A1 disclosing immunomodulating polynucleotides incorporating 5-modified uridine or cytidine, totaling 6-16 nucleotides in length, with optional abasic spacers and internucleoside phosphotriesters. The application further discloses conjugates pairing these polynucleotides with targeting moieties, and pharmaceutical compositions including stereochemically enriched internucleoside phosphorothioates. CPC classifications span C07K (peptides), C07H (nucleic acids), and A61K (preparations for medical purposes) with particular focus on C07K 16/28 (antibodies targeting immune cell receptors) and A61P 35/00 (antineoplastic agents).
Pharmaceutical and biotechnology companies developing immunotherapeutic agents should review the application's broad claims covering polynucleotide-antibody conjugate compositions and stereochemistry-enriched phosphorothioate modifications, which may encompass their current research programs or future product development strategies.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
Application US20260109728A1 Kind: A1 Apr 23, 2026
Inventors
Sukumar SAKAMURI, Curt W. BRADSHAW, Son LAM, Joseph STOCK, Edward HyungSuk HA, Laxman ELTEPU, Dingguo LIU, Bin LIU, Giuseppe Dello IACONO, Bryan R. MEADE, Ayman KABAKIBI
Abstract
Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.
CPC Classifications
C07H 21/04 A61K 31/7125 A61K 39/0011 A61K 39/39 A61K 40/10 A61K 40/19 A61K 40/24 A61K 40/421 A61K 40/4212 A61K 47/60 A61K 47/6807 A61K 47/6849 A61K 47/6883 A61P 35/00 C07K 7/06 C07K 16/2803 C07K 16/2812 C07K 16/2815 C07K 16/2818 C07K 16/2827 C07K 16/2833 C07K 16/2851 C07K 16/2863 C07K 16/2878 C07K 16/2887 C07K 16/2896 C07K 16/3084 C12N 15/117 A61K 2039/505 A61K 2039/507 A61K 2039/53 A61K 2039/54 A61K 2039/55516 A61K 2039/55561 A61K 2039/572 A61K 2239/31 A61K 2239/38 A61K 2239/48 A61K 2239/50 A61K 2239/57 C07K 2319/40 C12N 2310/17 C12N 2310/311 C12N 2310/315 C12N 2310/332 C12N 2310/3513 C12N 2310/3515 C12N 2310/51
Filing Date
2025-05-28
Application No.
19221414
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.